However, the marked downregulation of C5aR in both subcutaneous and omental depots of obese women in this study raises an interesting question: could C5aR antagonists, which are currently being used in Phase I and II clinical trials for treatment of asthma, psoriasis, and rheumatoid arthritis [19], have additional metabolic-related effects? Here, C5AR1 is linked to psoriasis.